Greenwich LifeSciences Announces Option Agreement for Pre-clinical Coronavirus Vaccine Candidates
December 15 2020 - 5:00AM
Business Wire
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a
clinical-stage biopharmaceutical company focused on the development
of GP2, an immunotherapy to prevent breast cancer recurrences in
patients who have previously undergone surgery, today announced
that it has entered into an option agreement with Westport Bio,
exercisable at the sole discretion of the Company, to in-license a
pre-clinical coronavirus vaccine program that is currently at the
stage of pre-clinical animal testing. In exchange for the option,
the Company has agreed to sponsor research in an aggregate amount
of up to $250,000 plus additional license and assignment fees.
Westport Bio’s coronavirus vaccine program includes up to 7 vaccine
candidates which are designed to complement or improve upon the
DNA/RNA based coronavirus vaccines that are in advanced Phase III
clinical trials or that have recently been approved by the FDA for
emergency use.
Westport Bio’s previous collaboration with an academic team led
to a pre-clinically developed vaccine that showed 100% protection
against a lethal challenge dose of pneumonic plague in non-human
primate and rodent animal models. The collaboration has been
expanded to include a coronavirus vaccine program using similar
technology. The coronavirus vaccine technology makes use of
multiple antigens that would complement strategies that rely solely
on the spike protein as the principal antigen. The spike protein of
SARS-CoV-2 plays a key role in the receptor recognition and cell
membrane fusion process, but there are also other antigens that may
be potential targets. In combination, these antigens may offer
greater protection and longer duration of protection.
Snehal Patel, CEO of Greenwich LifeSciences, commented, “While
we are focused on the upcoming GP2 Phase III breast cancer clinical
trial, and are also exploring how to expand the use of GP2 in
additional indications through supplemental clinical trials, we
have decided to explore the addition of new immunotherapy product
candidates to our pipeline at both the pre-clinical and clinical
stages of development. The objective of the coronavirus vaccine
program is to leverage the development team’s experience in
achieving 100% protection against lethal levels of pneumonic plague
infection to increase the percent protection and duration of
protection of coronavirus vaccines under development. It is not
clear how long one will be protected by the current Covid-19
vaccines and none that have been developed to date offer 100%
protection. We are hopeful that our approach, which showed 100%
protection against pneumonic plague, may lead to greater and longer
lasting protection compared to existing Covid-19 vaccines under
development.”
About Westport Bio
Westport Bio is a Texas LLC focused on multi-antigen vaccine
technology. The founder of Westport Bio is Snehal Patel, CEO of
Greenwich LifeSciences.
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical
company focused on the development of GP2, an immunotherapy to
prevent breast cancer recurrences in patients who have previously
undergone surgery. GP2 is a 9 amino acid transmembrane peptide of
the HER2/neu protein. In a randomized, single-blinded,
placebo-controlled, multi-center (16 sites led by MD Anderson
Cancer Center) Phase IIb clinical trial, no recurrences were
observed in the HER2/neu 3+ adjuvant setting after median 5 years
of follow-up, if the patient received the 6 primary intradermal
injections over the first 6 months (p = 0.0338). Of the 138
patients that have been treated with GP2 to date over 4 clinical
trials, GP2 treatment was well tolerated and no serious adverse
events were observed related to GP2 immunotherapy. Greenwich
LifeSciences is planning to commence a Phase III clinical trial
using a similar treatment regime as the Phase IIb clinical trial.
For more information on Greenwich LifeSciences, please visit the
company’s website: www.greenwichlifesciences.com
Forward-Looking Statement Disclaimer
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” “will,” “would,” or the negative of
these words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements are based on Greenwich LifeSciences Inc.’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. These and other risks and
uncertainties are described more fully in the section titled “Risk
Factors” in the final prospectus related to the public offering
filed with the Securities and Exchange Commission. Forward-looking
statements contained in this announcement are made as of this date,
and Greenwich LifeSciences Inc. undertakes no duty to update such
information except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201215005439/en/
Company Contact Snehal Patel Investor Relations (832)
819-3232 info@greenwichlifesciences.com
Investor & Public Relations Contact for Greenwich
LifeSciences Dave Gentry RedChip Companies Inc. Office:
1-800-RED CHIP (733 2447) Cell: (407) 491-4498 dave@redchip.com
Greenwich LifeSciences (NASDAQ:GLSI)
Historical Stock Chart
From Apr 2024 to May 2024
Greenwich LifeSciences (NASDAQ:GLSI)
Historical Stock Chart
From May 2023 to May 2024